Table 1

Baseline demographics and clinical characteristics (randomized population)

iGlarLixi (n = 469)iGlar (n = 467)Lixi (n = 234)All (N = 1,170)
Age (years)58.2 ± 9.558.3 ± 9.458.7 ± 8.758.4 ± 9.3
Sex
 Male222 (47.3)237 (50.7)133 (56.8)592 (50.6)
 Female247 (52.7)230 (49.3)101 (43.2)578 (49.4)
Race
 Caucasian417 (88.9)421 (90.1)216 (92.3)1,054 (90.1)
 Black33 (7.0)33 (7.1)12 (5.1)78 (6.7)
 Asian/Oriental8 (1.7)7 (1.5)3 (1.3)18 (1.5)
 Other11 (2.3)6 (1.3)3 (1.3)20 (1.7)
Ethnicity
 Hispanic85 (18.1)87 (18.6)51 (21.8)223 (19.1)
 Non-Hispanic384 (81.9)380 (81.4)183 (78.2)947 (80.9)
Duration of diabetes (years)8.9 ± 5.58.7 ± 5.68.9 ± 6.38.8 ± 5.7
Baseline BMI (kg/m2)31.6 ± 4.431.7 ± 4.532.0 ± 4.431.7 ± 4.4
Patients with BMI ≥30 kg/m262.961.767.963.4
HbA1c at screening
 %8.2 ± 0.78.2 ± 0.78.3 ± 0.78.2 ± 0.7
 mmol/mol66666766
HbA1c at baseline
 %8.1 ± 0.78.1 ± 0.78.1 ± 0.78.1 ± 0.7
 mmol/mol65656565
 Patients with HbA1c ≥8% (64 mmol/mol)55.955.756.055.8
Baseline FPG (mmol/mol)9.9 ± 2.49.8 ± 2.39.8 ± 2.29.8 ± 2.3
Baseline metformin dose (mg)2,246 ± 4572,245 ± 4452,267 ± 4272,250 ± 446
Second oral glucose-lowering therapy use at screening
 Yes58.457.856.857.9
 Sulfonylurea55.253.352.653.9
 Glinide0.62.12.11.5
 SGLT-2 inhibitor0.40.400.3
 DPP-4 inhibitor2.62.42.12.4
  • Data are mean ± SD, n (%), or %. Screening values are at week −6; baseline values are at week −1. DPP-4, dipeptidyl peptidase 4; SGLT-2, sodium-glucose cotransporter 2.